Accessibility Menu
Beyond Air logo

Beyond Air(NASDAQ) XAIR

Market Cap$4.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year-86%
1 Month+13%
$6.32
-8.74%
-0.61Today
Beyond Air last closing stock price
MetricPriceDate
Last closeUSD 6.322026-08-14
Beyond Air stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+17.82%USD 5.362026-08-07
1 month+12.57%USD 5.612026-07-15
3 month-36.58%USD 9.962026-05-15
Year to date-56.51%USD 14.522025-12-31
1 year-86.39%USD 46.402025-08-14
3 year-99.52%USD 1,304.002023-08-15
5 year-99.8%USD 3,128.002021-08-13
Since inception-99.75%USD 2,500.002017-07-11

Beyond Air Financials at a Glance

Market Cap

$4.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$7.69M

Net Income (TTM)

-$33.49M

EPS (TTM)

-$68.49

P/E Ratio

-0.09

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Price

$6.32

Volume

15,347

Open

$6.98

Previous Close

$6.32

Daily Range

$6.22 - $7.00

52-Week Range

$5.02 - $95.60

Estimated Earnings Date

Nov 16, 2026

XAIR News

Foolcom-Featured.png

Beyond Air Sales Jump 158 Percent

Motley Fool Markets TeamAug 18, 2025
frowning man

Why Beyond Air Stock Is Tanking Today

George Budwell, PhDDec 9, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Beyond Air

Beyond Air makes medical devices that help treat serious lung conditions. Its main product delivers nitric oxide gas to newborns with breathing problems. Hospitals use these devices to improve patient care and reduce treatment risks.

Gadgets That Breathe Easy: Products and Services

  • LungFit PH (100% revenue): Device for newborns with persistent pulmonary hypertension, used in hospitals.
  • LungFit PRO: In development for viral lung infections, such as pneumonia and COVID-19, for hospitalized patients.
  • LungFit GO: In development for treating nontuberculous mycobacteria, a rare lung infection.
  • Beyond Cancer: Ultra-high concentration nitric oxide therapy for solid tumors, in early clinical trials.
  • NeuroNOS: Preclinical program for neurological conditions, starting with autism spectrum disorder.
  • Device Services: Leasing, consumables, maintenance, and training for hospital clients using LungFit PH.

Plot Twists and Power Moves: Growth and Expansion

  • Launched LungFit PH in the US after FDA approval in 2022.
  • Secured CE Mark and expanded LungFit PH to Europe and Asia in 2023-2025.
  • Formed distribution partnerships with companies in France, India, Italy, Japan, Morocco, Saudi Arabia, and Turkey since 2023.
  • Advanced Beyond Cancer’s UNO therapy to phase 1b trials in 2025.
  • Raised $2.4 million through an at-the-market equity offering in Q2 2025.

Why Beyond Air Stands Out (Without Hot Air)

Beyond Air’s patented technology generates nitric oxide from room air, removing the need for gas cylinders. Its devices are approved in multiple countries, supporting a global hospital client base. The company operates across respiratory, oncology, and neurology markets, diversifying its risk and opportunity.

Five Things You Need to Know

  • Revenue was $2 million in Q2 2026, up 127.8% from Q2 2025.
  • Net loss was $8 million in Q2 2026, improving 40.3% year-over-year.
  • Cash used in operations was $4 million in Q2 2026, a 66.6% improvement.

Bottom Line

Beyond Air has shifted from research to commercial sales, focusing on hospital respiratory care. Its technology and global reach support ongoing diversification and adaptation in a competitive market.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

54

CEO

Robert Scott Goodman

Website

www.beyondair.net

Headquarters

Garden City, NY 11530, US

XAIR Financials

Key Financial Metrics (TTM)

Gross Margin

4.18%

Operating Margin

-364.76%

Net Income Margin

-435.71%

Return on Equity

-462.50%

Return on Capital

-98.42%

Return on Assets

-101.83%

Earnings Yield

-11.11%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

720.50K

Volume

15.35K

Avg. Volume

25.51K

Financials (TTM)

Gross Profit

$321.00K

Operating Income

-$28.04M

EBITDA

-$31.09M

Operating Cash Flow

-$18.56M

Capital Expenditure

-$1.04M

Free Cash Flow

-$19.60M

Cash & ST Invst.

$9.81M

Total Debt

$1.43M

Beyond Air Performance Analysis

Beyond Air annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 0N/A
20242024-03-31USD 1,159,000N/A
20252025-03-31USD 3,705,000219.7%
20262026-03-31USD 7,679,000107.3%
Beyond Air sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-303.3%
Q32025-12-3120.7%
Q42026-03-31-13.1%
Q12026-06-30-7.3%
Beyond Air annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -744.8710.7%
20242024-03-31USD -726.68-2.4%
20252025-03-31USD -275.45-62.1%
20262026-03-31USD -80.11-70.9%
Beyond Air sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-3018.3%
Q32025-12-3132.0%
Q42026-03-3196.5%
Q12026-06-30-1733.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

$1.77M

+0.5%

Gross Profit

$225.00K

+44.2%

Gross Margin

12.73%

N/A

Market Cap

$4.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$84.26K

N/A

Employees

54

N/A

Net Income

-$7.94M

-3.2%

EBITDA

-$6.46M

+2.2%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

$9.81M

+51.8%

Total Debt

$1.43M

-89.6%

Accounts Receivable

$1.14M

+11.4%

Inventory

$1.29M

-46.9%

Long Term Debt

$977.00K

-92.5%

Short Term Debt

$454.00K

-29.8%

Return on Assets

-1.02%

N/A

Return on Invested Capital

-1.08%

N/A

Free Cash Flow

-$5.15M

-9.1%

Operating Cash Flow

-$4.95M

-9.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BOLTBolt Biotherapeutics, Inc.
$3.35+4.36%
TNONTenon Medical, Inc.
$5.16-13.42%
CODXCo-Diagnostics, Inc.
$1.40-6.04%
LYRALyra Therapeutics, Inc.
$0.25+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About XAIR

What is the current price of Beyond Air?

Beyond Air is trading at $6.32 per share.

What is the 52-week range for Beyond Air?

Over the past 52 weeks, Beyond Air has traded between $5.02 and $95.60.

How much debt does Beyond Air have?

As of the most recent reporting period, Beyond Air reported total debt of $23.60M.

How much cash does Beyond Air have on hand?

Beyond Air reported $10.91M in cash and cash equivalents in its most recent financial results.

What is Beyond Air’s dividend yield?

Beyond Air does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services